The first patient has been dosed in the phase 2 DAVIO 2 clinical trial assessing EYP-1901 for the treatment of wet age-related macular degeneration, according to a press release from EyePoint Pharmaceuticals.
The 12-month randomized controlled trial will enroll approximately 150 patients with wet AMD previously treated with a standard-of-care anti-VEGF therapy. They will be randomly assigned to receive either one of two doses of EYP-1901, approximately 2 mg or 3 mg, or an aflibercept control.
Change in best corrected visual acuity, the primary efficacy endpoint, will be compared with